Roche extended its strong run into the second quarter of 2013, driven by its existing portfolio of cancer drugs like Avastin (bevacizumab), Lucentis (ranibizumab) and Herceptin (trastuzumab), recently launched cancer medicines Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) and continued growth in the group’s clinical laboratory business, CEO Severin Schwan told an investor call July 25.
He promised Roche will keep coming up with new cutting-edge products, adding: “We will continue to focus on innovation with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?